Scarica l'app Stockscreener
0.358
4.07%
0.014
Pre-mercato:
.37
0.012
+3.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Precedente Chiudi:
$0.344
Aprire:
$0.341
Volume 24 ore:
703.81K
Relative Volume:
0.85
Capitalizzazione di mercato:
$17.77M
Reddito:
$1.38M
Utile/perdita netta:
$-179.05M
Rapporto P/E:
-0.0583
EPS:
-6.14
Flusso di cassa netto:
$-155.03M
1 W Prestazione:
+0.36%
1M Prestazione:
+4.99%
6M Prestazione:
-69.40%
1 anno Prestazione:
-86.07%
Intervallo 1D:
$0.3401
$0.3665
Intervallo di 1 settimana:
$0.325
$0.3665
Portata 52W:
$0.3001
$4.17
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Nome
Bioxcel Therapeutics Inc
Settore
Industria
Telefono
203-643-8060
Indirizzo
555 LONG WHARF DRIVE, NEW HAVEN, CT
Confronta BTAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
0.358 | 17.77M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-21 | Downgrade | UBS | Buy → Neutral |
| 2023-08-15 | Downgrade | Mizuho | Buy → Neutral |
| 2023-07-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-03-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-01 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-06 | Reiterato | BofA Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-30 | Iniziato | Goldman | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-04 | Iniziato | Guggenheim | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
Mostra tutto
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
Why BioXcel Therapeutics Shares Are Rising Tuesday - MSN
BioXcel Therapeutics expands board, appoints new director - MSN
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Sees Large Drop in Short Interest - Defense World
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares Sold by Jane Street Group LLC - Defense World
Bioxcel Therapeutics Appoints Dr. Rajiv Patni to Board - TipRanks
Thinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin? - Marketscreener.com
BioXcel Therapeutics files to sell 5.1M shares of common stock by selling shareholders - MSN
BioXcel Therapeutics Amends Employment Agreements for Executives - Defense World
BioXcel Therapeutics (NASDAQ:BTAI) Earns “Underperform” Rating from Bank of America - Defense World
BioXcel Therapeutics amends executive compensation - Investing.com
BioXcel Therapeutics amends executive compensation By Investing.com - Investing.com UK
Top execs at New Haven-based BioXcel face compensation reductions amid company’s financial struggles - Hartford Business Journal
Are Investors Keen On Selling Holdings In BioXcel Therapeutics Inc (NASDAQ: BTAI)? - Stocks Register
Bioxcel Therapeutics Revises Executive Compensation Structure - TipRanks
BioXcel Therapeutics (NASDAQ:BTAI) Price Target Lowered to $5.00 at Canaccord Genuity Group - Defense World
State Street Corp Sells 47,600 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) - Defense World
BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade - MSN
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares Sold by BNP Paribas Financial Markets - Defense World
Bioxcel therapeutics CEO sells shares worth $1,131 By Investing.com - Investing.com South Africa
Bioxcel therapeutics CFO Richard Steinhart sells $206 in stock By Investing.com - Investing.com Nigeria
Bioxcel therapeutics executive sells $153 in stock By Investing.com - Investing.com Australia
Bioxcel therapeutics' chief scientific officer sells $151 worth of stock By Investing.com - Investing.com Canada
Bioxcel therapeutics CFO Richard Steinhart sells $206 in stock - Investing.com India
Bioxcel therapeutics executive sells $153 in stock - Investing.com
Bioxcel therapeutics CEO sells shares worth $1,131 - Investing.com
Bioxcel therapeutics exec sells $58 in stock By Investing.com - Investing.com UK
BioXcel Therapeutics stock hits 52-week low at $0.35 - Investing.com India
BioXcel Therapeutics stock hits 52-week low at $0.35 By Investing.com - Investing.com Nigeria
BioXcel Therapeutics (STU:BX2) 5-Day RSI : 7.74 (As of Dec. 05, 2024) - GuruFocus.com
BioXcel Therapeutics stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada
BioXcel Therapeutics stock hits 52-week low at $0.4 - Investing.com India
BioXcel Therapeutics announces pricing of $7M public offering - MSN
BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia
BioXcel Therapeutics Prices of $7 Million Public Offering - citybiz
BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India
BioXcel Therapeutics announces $7M public offering - Hartford Business Journal
BioXcel Prices New Offering - Baystreet.ca
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering - GlobeNewswire
BioXcel Therapeutics Announces $7M Public Offering at $0.48 Per Share with Warrants | BTAI Stock News - StockTitan
Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):